<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04021810</url>
  </required_header>
  <id_info>
    <org_study_id>38RC17.350</org_study_id>
    <nct_id>NCT04021810</nct_id>
  </id_info>
  <brief_title>Combination Therapy Associating CPAP and Mandibular Advancement Device in OSA</brief_title>
  <acronym>PPC-OAM</acronym>
  <official_title>Combination Therapy Associating CPAP and Mandibular Advancement Device ( MAD) in Obstructive Sleep Apnea (OSA) Low CPAP Compliers: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ONIRIS</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy of a combination of Continuous Positive
      Airway Pressure (CPAP) and a Mandibular Advancement Device (MAD) on nocturnal Blood Pressure
      control in hypertensive patients in obstructive sleep apnea low CPAP compliers (less than 4
      hours per night).

      Hypertensive patients demonstrating low CPAP adherence will be selected during a screening
      visit; they will be then randomized to one of the three following arms: Education to CPAP
      (&quot;CPAP only&quot;), Treatment by a MAD (&quot;MAD only&quot;) or a combination of both CPAP and MAD
      (&quot;CPAP+MAD&quot;). Mean systolic, diastolic, diurnal and nocturnal blood pressure will be assessed
      during 24-h Ambulatory Blood Pressure monitoring, before and after a 3-month treatment
      intervention. Biological laboratory parameters, patients reported outcomes (daytime
      sleepiness and Quality of Life), will also be evaluated before and after 3 months of
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to test the efficacy of a combination of Continuous Positive Airway
      Pressure (CPAP) treatment and a Mandibular Advancement Device (MAD) on the control of
      nocturnal Blood Pressure over a 3-month period in hypertensive obstructive sleep apnea being
      low CPAP compliers.

      This is a prospective, randomized, open-label and multi-centric study. The investigators plan
      to include 105 hypertensive patients demonstrating low CPAP adherence (less than 4 hours per
      night). Patients will be randomly assigned to one of the following treatments: Education for
      improving CPAP adherence ('CPAP Only' group: patients will continue their CPAP treatment and
      be supported by regular coaching aimed at increasing their compliance to treatment);
      Mandibular Advancement Device ('MAD Only' group: patients will switch their treatment from
      CPAP to a MAD); a combination of CPAP and MAD ('CPAP + MAD' group: patients will be treated
      by both devices used simultaneously).

      The duration of the study is 3 months. At the selection visit, patients will undergo a
      polysomnography/respiratory polygraphy followed by 24h- Ambulatory Blood Pressure Monitoring,
      PROMs (Quality of Life, Epworth Sleepiness Score) and a blood sample for biological
      parameters analysis. Patients will be then randomized to one of the three groups. Patients
      assigned to the 'CPAP only group' will be contacted by the homecare provider to arrange
      coaching sessions in order to improve their compliance to CPAP (phone calls and/or home
      visits). Patients assigned to the 'MAD Only group' will be proposed a Mandibular Advancement
      Device. Patients assigned to the 'CPAP+MAD group' will have both CPAP (with coaching) and a
      MAD.

      After a 3-month treatment period, the same measurements (24h-Ambulatory Blood pressure,
      polysomnography/respiratory polygraphy, questionnaires, and blood sample analysis) will be
      repeated to compare efficacy of the 3 interventions. Tolerance (number of adverse events) and
      adherence to treatments will also be assessed.

      The 'CPAP+MAD' group will be compared to the other two groups in order to evaluate the
      benefit of the combination therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2019</start_date>
  <completion_date type="Anticipated">April 18, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 18, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nightime Mean Blood Pressure</measure>
    <time_frame>3 months</time_frame>
    <description>Difference in nighttime Mean Blood Pressure before and after treatment, measured by ambulatory blood pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other 24h ambulatory blood pressure measurements</measure>
    <time_frame>3 months</time_frame>
    <description>24h ambulatory blood pressure measurements (systolic, diastolic and mean, diurnal and nocturnal) before and after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure Variability</measure>
    <time_frame>3 months</time_frame>
    <description>Blood Pressure variability before and after treatment, measured by ambulatory blood pressure measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Dippers/dipping phenotypes</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of dipper patients (&gt;10% drop in nocturnal Blood Pressure compared with daytime BP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-days home Blood Pressure measurements (systolic, diastolic)</measure>
    <time_frame>3 months</time_frame>
    <description>self-measurement of Systolic and Diastolic Blood Pressure, measured over 3 days, twice a day, before and after interventions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth Score</measure>
    <time_frame>3 months</time_frame>
    <description>Score on the Epworth Sleepiness Questionnaire, before and after treatment. The ESS is a self-administered questionnaire with 8 questions. Patients are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities. The ESS score (the sum of 8 sub-item scores( 0-3) can range from 0 to 24. The higher the ESS score the greater the likelihood that the person has daytime sleepiness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life score</measure>
    <time_frame>3 months</time_frame>
    <description>Score on the Quality Of Life Questionnaire SF12, before and after treatment. The SF-12 is a self-administered short survey with 12 questions assessing quality of life. The questions are combined, scored, and weighted to create two subscales (mental and social score and physical score) that provide glimpses into health-related quality of life. The lower the scores the more disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of Cholesterol</measure>
    <time_frame>3 months</time_frame>
    <description>Serum concentration of low-density lipoprotein cholesterol (LPL-C) and high-density lipoprotein cholesterol (HDL-C), before and after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of Triglycerides</measure>
    <time_frame>3 months</time_frame>
    <description>Serum concentration of Triglyceride, before and after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of fasting Glucose</measure>
    <time_frame>3 months</time_frame>
    <description>Concentration of fasting glucose, before and after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of HbA1C</measure>
    <time_frame>3 months</time_frame>
    <description>Amount of HbA1c, before and after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events related to the treatment</measure>
    <time_frame>3 months</time_frame>
    <description>Number of adverse events related to the treatment during the 3-month period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance to treatment(s)</measure>
    <time_frame>3 months</time_frame>
    <description>Use of the device(s) defined by number of hour per night and number of night per week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy determined by comparison of Apnea-Hypopnea Index (AHI), number of central and obstructive apneas and hypopneas, before and after treatment</measure>
    <time_frame>3 months</time_frame>
    <description>AHI, central and obstructive apneas and hyponeas index, measured by polysomnography or polygraphy, before and after treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Obstructive Sleep Apnea Syndrome</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>CPAP only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Obstructive sleep apnea patients with CPAP treatment only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mandibular Advancement Device only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Obstructive sleep apnea patients with Mandibular Advancement Device only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CPAP + Mandibular Advancement Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Obstructive sleep apnea patients with combined CPAP and Mandibular Advancement Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous Positive Airway Pressure (CPAP) and patient education</intervention_name>
    <description>Mask connected to a pump (CPAP machine) that forces air into the nasal passages at pressures high enough to overcome obstructions in the airways. Plus patient education.</description>
    <arm_group_label>CPAP + Mandibular Advancement Device</arm_group_label>
    <arm_group_label>CPAP only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mandibular Advancement Device</intervention_name>
    <description>Adjustable oral prosthesis which retains the lower mandible in an anterior position, thus limiting sleep apneas</description>
    <arm_group_label>CPAP + Mandibular Advancement Device</arm_group_label>
    <arm_group_label>Mandibular Advancement Device only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Arterial Hypertension (Clinical Blood Pressure &gt; 140/90 mmHg or patient under
             medication with nocturnal hypertension seen in the Ambulatory Blood Pressure
             Measurement)

          -  Severe obstructive sleep apnea syndrome, treated by CPAP for more than 6 months and
             less than 5 years, with a compliance &lt;4h/night

          -  No contraindication to a treatment by Mandibular Advancement Device

          -  Ability to understand study procedures and signed informed consent

          -  Covered by French social security system or equivalent

        Exclusion Criteria:

          -  Central Obstructive Apnea (&gt;20% Central Apneas/Hypopneas)

          -  Pregnant or breastfeeding womens

          -  Prisoners or persons who require protection by the law

          -  Persons within the exclusion period of another study

          -  Contraindication to a mandibular advancement device (oral-dental pathology, pathology
             of the temporo-mandibular articulation, poor periodontal status)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Louis Pépin, Pr, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Louis Pépin, Pr, PhD</last_name>
    <phone>+33 476 768 473</phone>
    <email>JPepin@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marjorie Dole, PhD</last_name>
    <phone>+33 476 766 918</phone>
    <email>mdole2@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nouvelle Clinique Bel Air</name>
      <address>
        <city>Bordeaux</city>
        <zip>33073</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Sapène, MD</last_name>
      <email>ml.sapene@orange.fr</email>
    </contact>
    <investigator>
      <last_name>Nathalie Raymond, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Louis Pepin, Pr, PhD</last_name>
      <phone>+33 476 768 473</phone>
      <email>JPepin@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marjorie Dole, PhD</last_name>
      <phone>+33 476 766 918</phone>
      <email>mdole2@chu-grenoble.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Renaud Tamisier, Pr, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Destors, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alain Verain, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile Chatel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arnaud Bourdin, MD</last_name>
      <email>a-bourdin@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Pierre Mallet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical</name>
      <address>
        <city>Perpignan</city>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier Lacaze, MD</last_name>
      <email>olivierlacaze@neuf.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993 Apr 29;328(17):1230-5.</citation>
    <PMID>8464434</PMID>
  </results_reference>
  <results_reference>
    <citation>Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet. 2005 Mar 19-25;365(9464):1046-53.</citation>
    <PMID>15781100</PMID>
  </results_reference>
  <results_reference>
    <citation>Kendzerska T, Gershon AS, Hawker G, Leung RS, Tomlinson G. Obstructive sleep apnea and risk of cardiovascular events and all-cause mortality: a decade-long historical cohort study. PLoS Med. 2014 Feb 4;11(2):e1001599. doi: 10.1371/journal.pmed.1001599. eCollection 2014 Feb.</citation>
    <PMID>24503600</PMID>
  </results_reference>
  <results_reference>
    <citation>Bailly S, Destors M, Grillet Y, Richard P, Stach B, Vivodtzev I, Timsit JF, Lévy P, Tamisier R, Pépin JL; scientific council and investigators of the French national sleep apnea registry (OSFP). Obstructive Sleep Apnea: A Cluster Analysis at Time of Diagnosis. PLoS One. 2016 Jun 17;11(6):e0157318. doi: 10.1371/journal.pone.0157318. eCollection 2016.</citation>
    <PMID>27314230</PMID>
  </results_reference>
  <results_reference>
    <citation>Lévy P, Kohler M, McNicholas WT, Barbé F, McEvoy RD, Somers VK, Lavie L, Pépin JL. Obstructive sleep apnoea syndrome. Nat Rev Dis Primers. 2015 Jun 25;1:15015. doi: 10.1038/nrdp.2015.15. Review.</citation>
    <PMID>27188535</PMID>
  </results_reference>
  <results_reference>
    <citation>Bratton DJ, Gaisl T, Schlatzer C, Kohler M. Comparison of the effects of continuous positive airway pressure and mandibular advancement devices on sleepiness in patients with obstructive sleep apnoea: a network meta-analysis. Lancet Respir Med. 2015 Nov;3(11):869-78. doi: 10.1016/S2213-2600(15)00416-6. Epub 2015 Oct 20. Erratum in: Lancet Respir Med. 2015 Dec;3(12):e44.</citation>
    <PMID>26497082</PMID>
  </results_reference>
  <results_reference>
    <citation>Pépin JL, Tamisier R, Baguet JP, Lepaulle B, Arbib F, Arnol N, Timsit JF, Lévy P. Fixed-pressure CPAP versus auto-adjusting CPAP: comparison of efficacy on blood pressure in obstructive sleep apnoea, a randomised clinical trial. Thorax. 2016 Aug;71(8):726-33. doi: 10.1136/thoraxjnl-2015-207700. Epub 2016 Apr 18.</citation>
    <PMID>27091542</PMID>
  </results_reference>
  <results_reference>
    <citation>Pépin JL, Tamisier R, Barone-Rochette G, Launois SH, Lévy P, Baguet JP. Comparison of continuous positive airway pressure and valsartan in hypertensive patients with sleep apnea. Am J Respir Crit Care Med. 2010 Oct 1;182(7):954-60. doi: 10.1164/rccm.200912-1803OC. Epub 2010 Jun 3.</citation>
    <PMID>20522795</PMID>
  </results_reference>
  <results_reference>
    <citation>Malhotra A, Orr JE, Owens RL. On the cutting edge of obstructive sleep apnoea: where next? Lancet Respir Med. 2015 May;3(5):397-403. doi: 10.1016/S2213-2600(15)00051-X. Epub 2015 Apr 14. Review.</citation>
    <PMID>25887980</PMID>
  </results_reference>
  <results_reference>
    <citation>Bratton DJ, Gaisl T, Wons AM, Kohler M. CPAP vs Mandibular Advancement Devices and Blood Pressure in Patients With Obstructive Sleep Apnea: A Systematic Review and Meta-analysis. JAMA. 2015 Dec 1;314(21):2280-93. doi: 10.1001/jama.2015.16303. Review.</citation>
    <PMID>26624827</PMID>
  </results_reference>
  <results_reference>
    <citation>Mokhlesi B, Hagen EW, Finn LA, Hla KM, Carter JR, Peppard PE. Obstructive sleep apnoea during REM sleep and incident non-dipping of nocturnal blood pressure: a longitudinal analysis of the Wisconsin Sleep Cohort. Thorax. 2015 Nov;70(11):1062-9. doi: 10.1136/thoraxjnl-2015-207231. Epub 2015 Aug 25.</citation>
    <PMID>26307037</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 18, 2019</study_first_submitted>
  <study_first_submitted_qc>July 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2019</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sleep Apnea</keyword>
  <keyword>CPAP</keyword>
  <keyword>Mandibular Advancement Device</keyword>
  <keyword>Arterial Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

